Targeted Thromboelastographic (TEG) Blood Component and Pharmacologic Hemostatic Therapy in Traumatic and Acquired Coagulopathy

Title:Targeted Thromboelastographic (TEG) Blood Component and Pharmacologic Hemostatic Therapy in Traumatic and Acquired Coagulopathy

Volume: 17 Issue: 8

Author(s): Mary K Bader, Francis J. Castellino, Victoria Ploplis, Faisal Shariff, Anton Crepinsek, Scott Thomas, Alyson Liew-Spilger, Sophia Binz, Jonathon McCollester, Mark Walsh, Adam Miller, Braxton Fritz, Swetha Chitta, Manar Jbara, Sarah Greve, Michael Son, Daniel Hake and Stephanie Fritz

Affiliation:

Keywords: Thromboelastography, point-of-care, acquired coagulopathy, blood component therapy, systemic hemostatic agents, trauma-induced coagulopathy, hemostatic resuscitation, tranexamic acid, targeted pharmacologic therapy.

Abstract: Trauma-induced coagulopathy (TIC) is a recently described condition which traditionally has been diagnosed by the common coagulation tests (CCTs) such as prothrombin time/international normalized ratio (PT/INR), activated partial thromboplastin time (aPTT), platelet count, and fibrinogen levels. The varying sensitivity and specificity of these CCTs have led trauma coagulation researchers and clinicians to use Viscoelastic Tests (VET) such as Thromboelastography (TEG) to provide Targeted Thromboelastographic Hemostatic and Adjunctive Therapy (TTHAT) in a goal directed fashion to those trauma patients in need of hemostatic resuscitation. This review describes the utility of VETs, in particular, TEG, to provide TTHAT in trauma and acquired non-trauma-induced coagulopathy.

Cite this article as:

K Bader Mary, J. Castellino Francis, Ploplis Victoria, Shariff Faisal, Crepinsek Anton, Thomas Scott, Liew-Spilger Alyson, Binz Sophia, McCollester Jonathon, Walsh Mark, Miller Adam, Fritz Braxton, Chitta Swetha, Jbara Manar, Greve Sarah, Son Michael, Hake Daniel and Fritz Stephanie, Targeted Thromboelastographic (TEG) Blood Component and Pharmacologic Hemostatic Therapy in Traumatic and Acquired Coagulopathy, Current Drug Targets 2016; 17 (8) . https://dx.doi.org/10.2174/1389450117666160310153211